OverviewSuggest Edit

Lonza (also known as Lonza Biologics) is a company that supplies active ingredients, chemical intermediates, and biotechnology solutions to the pharmaceutical and agrochemical industries. It also offers organic intermediates for a range of applications, such as pharmaceuticals, agrochemicals, vitamins, food and feedstuff, dyes and pigments, adhesives, and fragrances. The company also manufactures specialty biocides and oleochemicals; and develops and produces specific polymer intermediates, unsaturated polyester-resins, compounds, and composites.
TypePublic
Founded1897
HQBasel, CH
Websitelonza.com
Employee Ratings3.4
Overall CultureC+

Latest Updates

Employees (est.) (Jun 2020)15,913(+3%)
Revenue (FY, 2019)CHF5.9 B(+7%)
Share Price (Jan 2021)CHF587.4
Cybersecurity ratingAMore

Key People/Management at Lonza

Pierre-Alain Ruffieux

Pierre-Alain Ruffieux

Chief Executive Officer and Member of the Executive Committee
Caroline Barth

Caroline Barth

Chief Human Resources Officer and Member of the Executive Committee
Stefan Stoffel

Stefan Stoffel

Chief Operating Officer, Pharma & Biotech Segment and Member of the Executive Committee
Christoph Mäder

Christoph Mäder

Independent member of the Board of Directors
Werner Bauer

Werner Bauer

Independent member of the Board of Directors
Dorothée Deuring

Dorothée Deuring

Independent member of the Board of Directors
Show more

Lonza Office Locations

Lonza has offices in Basel, Monteggio, Stein, Visp and in 95 other locations
Basel, CH (HQ)
Lonza-Hochhaus, Münchensteinerstrasse 38
Basel, CH
Hochbergerstrasse 60A
Monteggio, CH
Via Cantonale 4
Stein, CH
Schaffhauserstrasse 101
Ingeniero Maschwitz, AR
Calle Septiembre 151
Bella Vista, AU
308/10 Norbrik Dr
Show all (105)

Lonza Financials and Metrics

Lonza Revenue

Embed Graph
View revenue for all periods
Lonza's revenue was reported to be CHF5.92 b in FY, 2019 which is a 6.8% increase from the previous period.
CHF

Revenue (H1, 2020)

3.1b

Revenue growth (H1, 2020 - H1, 2020), %

(48%)

Gross profit (H1, 2020)

1.2b

Gross profit margin (H1, 2020), %

39.8%

Net income (H1, 2020)

478.0m

EBITDA (H1, 2020)

893.0m

EBIT (H1, 2020)

618.0m

Market capitalization (15-Jan-2021)

43.6b

Closing stock price (15-Jan-2021)

587.4

Cash (30-Jun-2020)

552.0m

EV

46.9b
Lonza's current market capitalization is CHF43.6 b.
Annual
CHFFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

4.1b5.1b5.5b5.9b

Revenue growth, %

24%9%7%

Cost of goods sold

2.7b3.3b3.4b3.7b

Gross profit

1.4b1.8b2.1b2.3b
Half Year
CHFH1, 2017H1, 2018H1, 2019H1, 2020

Revenue

2.3b3.1b3.0b3.1b

Revenue growth, %

(48%)

Cost of goods sold

1.4b1.9b1.8b1.9b

Gross profit

883.0m1.2b1.1b1.2b
Annual
CHFFY, 2016FY, 2017FY, 2018FY, 2019

Cash

274.0m479.0m461.0m505.0m

Accounts Receivable

612.0m825.0m692.0m

Prepaid Expenses

54.0m88.0m181.0m

Inventories

897.0m1.2b1.3b
Half Year
CHFH1, 2017H1, 2018H1, 2019H1, 2020

Cash

3.2b488.0m413.0m552.0m

Current Assets

4.9b3.0b2.9b3.1b

Total Assets

9.6b14.0b13.5b13.9b

Short-term debt

248.0m946.0m637.0m330.0m
Annual
CHFFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

301.0m728.0m563.0m646.0m

Depreciation and Amortization

307.0m411.0m526.0m

Inventories

(19.0m)(22.0m)(207.0m)

Accounts Payable

(15.0m)35.0m77.0m
Half Year
CHFH1, 2017H1, 2018H1, 2019H1, 2020

Net Income

233.0m405.0m30.0m478.0m

Cash From Operating Activities

414.0m427.0m166.0m434.0m

Purchases of PP&E

(163.0m)(180.0m)(308.0m)(416.0m)

Cash From Investing Activities

(172.0m)(191.0m)269.0m(470.0m)
CHFFY, 2016

EV/EBITDA

12 x

EV/EBIT

21 x

EV/CFO

13.5 x

Revenue/Employee

411.9k

Debt/Equity

0.8 x

Debt/Assets

0.3 x

Financial Leverage

2.9 x

P/E Ratio

44.3
Show all financial metrics

Lonza Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Manufacturing and R&D Facilities

40 53 70 55

Patent Families

650 630 575

Countries

30 30 30 30

Clinical Development Programs (Pharma and Biotech)

350 575 730
Show all operating metrics

Lonza Acquisitions / Subsidiaries

Company NameDateDeal Size
Octane BiotechOctober 31, 20118chf58 m
Micro-MacinazioneJuly 26, 2017chf67 m
CapsugelJuly 05, 2017chf3.30 b
PharmaCellMay 03, 2017chf33 m
InterHealth NutraceuticalsSeptember 12, 2016chf240 m
Triangle Research LabsApril 27, 2016chf15 m
Diacon TechnologiesOctober 01, 2015chf12 m
Zelam HoldingsAugust 03, 2015
Arch Acquisition LLC
Arch Chemicals Canada, Inc.
Show more

Lonza Revenue Breakdown

Embed Graph

Lonza revenue breakdown by business segment: 70.3% from Pharma & Biotech, 28.7% from Specialty Ingredients and 1.0% from Other

Lonza revenue breakdown by geographic segment: 38.3% from EMEA, 15.3% from APAC and 46.4% from Americas

Human Capital Metrics

Lonza's employees are reported to be approximately 32% female and 68% male.
Embed Graph
Show all human capital metrics

Lonza Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Lonza Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Lonza Online and Social Media Presence

Embed Graph

Lonza Company Culture

  • Overall Culture

    C+

    67/100

  • CEO Rating

    A+

    79/100

  • Compensation

    A+

    89/100

  • Diversity

    C+

    66/100

Learn more on Comparably

Lonza News and Updates

Cytiva delivers modular biologics factory to Lonza

From site selection in Guangzhou Biopark to handover during the global pandemic, 17,000-square meter site was completed in less than two years From Lonza's first manufacturing site for biologics in China, the healthcare leader will provide services and manufacturing needed to respond to...

Cytiva Delivers Modular Biologics Factory to Lonza

Cytiva completed a KUBio installation for Lonza in Guangzhou Biopark, China. The high throughput modular biomanufacturing facility will offer process development and manufacturing for Chinese companies developing innovative medicines, as well as multinationals with manufacturing requirements in Chi…

Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

—Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply—

Lonza plant in Switzerland starts making ingredients for Moderna COVID shot

Contract drugmaker Lonza said on Monday it has begun manufacturing ingredients for Moderna Inc’s COVID-19 vaccine from the first of three new Swiss production lines and expects the initial batch to be ready by month’s end

Capricor Collaborates with Lonza for the Development of CAP-1002

Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza today announced that the companies have entered into an agreement for the development of…

Global Medium Chain Triglycerides Market Report 2020-2024 Featuring BASF, Croda Int'l, DuPont de Nemours, Koninklijke DSM, Lonza, Oleon & Wilmar International Among Others

Dublin, Jan. 08, 2021 (GLOBE NEWSWIRE) -- The "Global Medium Chain Triglycerides Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The medium chain triglycerides (MCT) market is poised to grow by $ 481.40 mn during 2020-2024 progressing at a CAGR of 8% during the fore…
Show more

Lonza Frequently Asked Questions

  • When was Lonza founded?

    Lonza was founded in 1897.

  • Who are Lonza key executives?

    Lonza's key executives are Pierre-Alain Ruffieux, Caroline Barth and Stefan Stoffel.

  • How many employees does Lonza have?

    Lonza has 15,913 employees.

  • What is Lonza revenue?

    Latest Lonza annual revenue is CHF5.9 b.

  • What is Lonza revenue per employee?

    Latest Lonza revenue per employee is CHF372 k.

  • Who are Lonza competitors?

    Competitors of Lonza include DuPont, Divis Laboratories and Royal DSM.

  • Where is Lonza headquarters?

    Lonza headquarters is located at Lonza-Hochhaus, Münchensteinerstrasse 38, Basel.

  • Where are Lonza offices?

    Lonza has offices in Basel, Monteggio, Stein, Visp and in 95 other locations.

  • How many offices does Lonza have?

    Lonza has 105 offices.